Travere Therapeutics (TVTX) Institutional Ownership
13F filers reported holding 24.4% of Travere Therapeutics (TVTX) shares as of Sep 30, 2026, across 158 filers.
- Held by 13F filers
- 24.4%
- Sep 30, 2026
- 13F filers
- 158
- quarter ended Sep 30, 2026
- 13F value
- $1.4B
- 23.5M shares
- Quarter's fund flow
- Mild accumulation
- 33 new · 15 closed
Is the smart money (institutions and insiders) accumulating or distributing? One lagging input, not a buy signal.
| Date | Name | Role | Type | Shares | Price** | SEC filing |
|---|---|---|---|---|---|---|
| Oct 15, 2026 | Dube Eric M | CHIEF EXECUTIVE OFFICER | Acquired · Option exercise | 43,735 | $26.88 | ↗ |
| Oct 15, 2026 | Dube Eric M | CHIEF EXECUTIVE OFFICER | Acquired · Option exercise | 200,000 | $8.93 | ↗ |
| Oct 15, 2026 | Dube Eric M | CHIEF EXECUTIVE OFFICER | Disposed · Open-market sale | 128,065 | $52.97 | ↗ |
| Oct 15, 2026 | Dube Eric M | CHIEF EXECUTIVE OFFICER | Disposed · Open-market sale | 37,270 | $54.20 | ↗ |
| Oct 15, 2026 | Dube Eric M | CHIEF EXECUTIVE OFFICER | Disposed · Open-market sale | 78,400 | $55.02 | ↗ |
| Oct 15, 2026 | Dube Eric M | CHIEF EXECUTIVE OFFICER | Disposed · Option exercise | 43,735Employee stock option (right to buy) | — | ↗ |
| Oct 15, 2026 | Dube Eric M | CHIEF EXECUTIVE OFFICER | Disposed · Option exercise | 200,000Employee stock option (right to buy) | — | ↗ |
| Sep 17, 2026 | Heerma Peter | EVP, CHIEF COMMERCIAL OFFICER | Acquired · Option exercise | 8,282 | $22.40 | ↗ |
| Sep 17, 2026 | Heerma Peter | EVP, CHIEF COMMERCIAL OFFICER | Disposed · Open-market sale | 8,282 | $65.07 | ↗ |
| Sep 17, 2026 | Heerma Peter | EVP, CHIEF COMMERCIAL OFFICER | Disposed · Option exercise | 8,282Employee stock option (right to buy) | — | ↗ |
| Sep 17, 2026 | Dube Eric M | CHIEF EXECUTIVE OFFICER | Acquired · Option exercise | 108,493 | $23.34 | ↗ |
| Sep 17, 2026 | Dube Eric M | CHIEF EXECUTIVE OFFICER | Disposed · Open-market sale | 101,691 | $64.59 | ↗ |
| Sep 17, 2026 | Dube Eric M | CHIEF EXECUTIVE OFFICER | Disposed · Open-market sale | 6,802 | $64.95 | ↗ |
| Sep 17, 2026 | Dube Eric M | CHIEF EXECUTIVE OFFICER | Disposed · Option exercise | 108,493Employee stock option (right to buy) | — | ↗ |
| Sep 16, 2026 | Heerma Peter | EVP, CHIEF COMMERCIAL OFFICER | Acquired · Option exercise | 100,000 | $11.25 | ↗ |
| Sep 16, 2026 | Heerma Peter | EVP, CHIEF COMMERCIAL OFFICER | Acquired · Option exercise | 55,000 | $15.46 | ↗ |
| Sep 16, 2026 | Heerma Peter | EVP, CHIEF COMMERCIAL OFFICER | Acquired · Option exercise | 17,717 | $26.88 | ↗ |
| Sep 16, 2026 | Heerma Peter | EVP, CHIEF COMMERCIAL OFFICER | Disposed · Open-market sale | 93,604 | $63.25 | ↗ |
| Sep 16, 2026 | Heerma Peter | EVP, CHIEF COMMERCIAL OFFICER | Disposed · Open-market sale | 79,113 | $63.65 | ↗ |
| Sep 16, 2026 | Heerma Peter | EVP, CHIEF COMMERCIAL OFFICER | Disposed · Option exercise | 100,000Employee stock option (right to buy) | — | ↗ |
* Holdings as reported for Sep 30, 2026, 49 days old; funds file up to 45 days after each quarter-end, so the newest complete quarter runs 45 to 135 days behind.
** A price of “—” marks an option exercise, RSU vest or a filing without a usable per-share price, not a $0 trade.
Common questions
How much of Travere Therapeutics do institutions hold?
13F filers reported holding 24.4% of Travere Therapeutics' shares as of Sep 30, 2026, across 158 filers.
How many 13F filers hold Travere Therapeutics?
Travere Therapeutics was held by 158 13F filers as of Sep 30, 2026.
Not investment advice.

